|
Kadmon Corporation (originally ''Kadmon Pharmaceuticals'') is a privately held biopharmaceutical company based in New York City. It also has operations in Warrendale, PA and Brighton, MA. The company was founded in 2009 by Samuel D. Waksal,〔(【引用サイトリンク】url=http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=114935891 )〕 founder and former CEO of ImClone Systems, now wholly owned by Eli Lilly and Company. Waksal had served a federal prison sentence stemming from his fiduciary role as CEO in the 2001 ImClone stock trading case. He was released in 2009 and cannot serve as an officer for any publicly traded company. Kadmon however is privately financed. In September 2014 Harlan W. Waksal, brother of Sam Waksal, became President and Chief Executive Officer of Kadmon and Sam Waksal became its Chief of Innovation, Science and Strategy. == Product Acquisitions == During Waksal's leadership of ImClone the company was engaged in early stage research projects for 15 years before filing its first drug application. Kadmon however immediately began acquiring drugs further advanced - either already marketed in the US or in the later stages of clinical development. It acquired the Warrendale, PA-based company Three Rivers Pharmaceuticals and their Ribasphere and topotecan products. It also signed an agreement with Ontario, Canada-based Valeant Pharmaceuticals for their Hepatitis C drugs ribavirin and taribavirin (now KD024). Cancer drugs XL647〔 and XL844〔 were acquired from Exelixis. An inhibitor of several protein kinases, XL647 (KD019) entered Phase II clinical trial for certain indications of non-small cell lung cancer. and in polycystic kidney disease. XL844 is an inhibitor of protein kinases Chk1 and Chk2 and may increase the sensitivity of cancer cells to radiation therapy. In an acquisition atypical for a biotechnology company, an 1800-year-old Chinese herbal formula was added to Kadmon's portfolio. PhytoCeutica's PHY906 (KD018) is a formula of four botanical products that had long been used for the treatment of gastrointestinal distress. Preclinical studies have shown it to enhance the therapeutic activity of several anticancer agents. In 2014 KD018 was in a Phase II trial in combination with irinotecan in metastatic colon cancer. In 2011 the company acquired rights from Brighton, MA-based Nano Terra Inc. for their ''Pharmacomer Technology'' research platform and three drug candidates in clinical development.〔(【引用サイトリンク】url=http://www.nanowerk.com/news/newsid=21135.php )〕 These compounds include SLx-2119 (KD025), an inhibitor to Rho kinase 2 (ROCK2) with possible potential in fibrotic disease and focal cerebral ischemia. SLx-4090 (KD026) is a triglyceride transfer protein (MTP) inhibitor being explored for metabolic disorders. SLx-2101 (KD027) is a phosphodiesterase 5 (PDE5) inhibitor, a class of drug used in the treatment of erectile dysfunction. In 2012 the rights to salirasib (''KD032''), a Ras antagonist in development for cancer therapy, were acquired from Concordia Pharmaceuticals of Fort Lauderdale, FL.〔(【引用サイトリンク】url=http://www.biospace.com/news_story.aspx?StoryID=245712 )〕 It also acquired the rights from Burlington, MA-based Dyax Corp. for DX-2400,〔(【引用サイトリンク】url=http://investor.dyax.com/releasedetail.cfm?ReleaseID=708254 )〕 a Matrix metalloproteinase-14 (MPP-14) tarageted monoclonal antibody intended to inhibit tumor blood vessel formation and metastasis. As of December 2012 Kadmon was developing a drug for gastric cancer 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Kadmon Corporation」の詳細全文を読む スポンサード リンク
|